Valuation: NuCana plc

Market Cap 3.04M 2.75M 2.55M 2.3M 4.33M 287M 4.48M 30.6M 12.14M 153M 11.41M 11.16M 486M P/E 2024
-0.15x
P/E 2025 -0.2x
Enterprise Value -20.54M -18.61M -17.21M -15.53M -29.27M -1.94B -30.3M -207M -81.99M -1.03B -77.06M -75.43M -3.28B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99%
Yield 2024 *
-
Yield 2025 -
1 day+0.28%
1 week-0.53%
Current month-7.65%
1 month-11.17%
3 months-36.98%
6 months-50.12%
Current year-74.09%
1 week 0.88
Extreme 0.875
1
1 month 0.88
Extreme 0.875
1.17
Current year 0.88
Extreme 0.875
3.81
1 year 0.88
Extreme 0.875
4.55
3 years 0.88
Extreme 0.875
3,882
5 years 0.88
Extreme 0.875
16,598.5
10 years 0.88
Extreme 0.875
160,000
Manager TitleAgeSince
Chief Executive Officer 58 2008-03-19
Director of Finance/CFO - 2018-12-31
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 58 2008-03-19
Director/Board Member 68 2009-12-13
Director/Board Member 72 2018-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
4/15/26 Free

Chief Operating Officer

132,600,130 -
3/18/26 Other

Head of Translational Medicine

283,984,182 -
3/18/26 Other

Founder

4,352,841,381 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%-0.53%-73.28%-99.95% 4.02M
-2.69%-0.48%+51.67%+69.09% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
Average -0.53%-0.01%+26.66%+159.78% 41B
Weighted average by Cap. -0.83%+0.20%+37.23%+162.19%

Financials

2024 2025
Net sales - -
Net income -19M -17.22M -15.92M -14.37M -27.07M -1.79B -28.03M -191M -75.85M -957M -71.29M -69.78M -3.04B -29.35M -26.6M -24.6M -22.2M -41.83M -2.77B -43.31M -296M -117M -1.48B -110M -108M -4.69B
Net Debt -6.56M -5.94M -5.5M -4.96M -9.35M -618M -9.68M -66.04M -26.19M -330M -24.61M -24.09M -1.05B -23.58M -21.36M -19.76M -17.83M -33.6M -2.22B -34.78M -237M -94.12M -1.19B -88.47M -86.59M -3.77B
Projected Income Statement - Annual - NuCana plc
Logo NuCana plc
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Employees
11
Date Price Change Volume
26-11-13 US$0.9327 +0.28% 14,000
26-11-12 US$0.9300 -1.04% 31,899
26-11-11 US$0.9398 +0.51% 41,641
26-11-10 US$0.9350 -2.67% 13,183
26-11-09 US$0.9606 +2.44% 14,334

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - NuCana plc
  1. Stock Market
  2. Stocks
  3. NCNA Stock